Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Lankenau Medical Center, Pennsylvania Clinical Trials

A listing of Lankenau Medical Center, Pennsylvania clinical trials actively recruiting patient volunteers.

RESULTS

Found (191) clinical trials

Accelerated Hypofractionated or Conventionally Fractionated Radiotherapy and Durvalumab in Treating Patients With Stage II-III Non-small Cell Lung Cancer

PRIMARY OBJECTIVE: I. To evaluate if the addition of MEDI4736 (durvalumab) to two schedules of radiation therapies (60 Gy in 30 fractions or 60 Gy in 15 fractions) is safe. SECONDARY OBJECTIVES: I. To examine if the addition of MEDI4736 (durvalumab) to radiation therapy is feasible. II. To assess toxicities ...

Phase

1.09 miles

Learn More »

A Study of Cetrelimab (JNJ-63723283) a Programmed Cell Death Receptor-1 (PD-1) Inhibitor Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

This study is of participants originally diagnosed with adenocarcinoma of the prostate who have now developed mCRPC and who have progressed on therapy with abiraterone acetate plus prednisone/prednisolone (AA-P), apalutamide, darolutamide, or enzalutamide. Participants with treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) assessed by the screening biopsy may be considered for ...

Phase

2.19 miles

Learn More »

CAR T Cell Immunotherapy for Pancreatic Cancer

This is a Phase I study evaluating the feasibility of producing as well as the safety of administering lentiviral transduced huCART-meso cells in up to three (3) cohorts both with and without cyclophosphamide in a three-plus-three (3+3) dose escalation design. Cohort 1(N=3-6): subjects will receive a single dose of 1-3x10^7/m^2 ...

Phase

3.73 miles

Learn More »

Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction

Physically healthy adult smokers may be eligible for this study. Volunteers may participate in this study if they are 18 - 65 years old. Subjects will participate in two separate 10-hour PET/CT Scan Sessions (each with 2 hours of actual PET/CT scanning): one following an overnight abstinence and one following ...

Phase

3.73 miles

Learn More »

MDM2 Inhibitor AMG-232 in Treating Patients With Recurrent or Newly Diagnosed Glioblastoma

PRIMARY OBJECTIVES: I. Determine the concentration and variability in concentration of MDM2 inhibitor AMG-232 (AMG 232) in brain and brain-associated tissue in patients with recurrent glioblastoma (GBM). (Part 1) II. Determine the maximum tolerated dose (MTD) of AMG 232 given in combination with standard radiation following surgery for patients with ...

Phase

3.73 miles

Learn More »

Phase 1 Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma

The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-6527, and to assess the safety, tolerability and pharmacokinetics of H3B-6527.

Phase

3.73 miles

Learn More »

Vincristine Sulfate Liposome Injection (Marqibo ) in Combination With UK ALL R3 Induction Chemotherapy for Children Adolescents and Young Adults With Relapsed ALL

This study will utilize Marqibo as a replacement for standard vincristine in combination with UK ALL R3 induction for children with relapsed ALL. The hypothesis is that the incorporation of Marqibo with combination chemotherapy will be safe and feasible. In the context of this pilot study, overall outcomes and efficacy ...

Phase

3.73 miles

Learn More »

Safety Study of BTK Inhibitor DTRMWXHS-12 Used Singly or in Combination in CLL and B-cell Lymphomas

This study will evaluate the safety, antitumor activity and preliminary pharmacokinetics of an investigational drug product, DTRMWXHS-12, in patients with chronic lymphocytic leukemia or other B-cell lymphomas. DTRMWXHS-12 will be evaluated as a single agent, and in combination. This study will be conducted in two parts: phase Ia and Ib. ...

Phase

3.73 miles

Learn More »

Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors CNS Tumors or Lymphoma

This is a Phase I clinical trial. A Phase I clinical trial tests the safety of an investigational intervention and also tries to find the best dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied. The FDA (the U.S. Food and ...

Phase

3.73 miles

Learn More »

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

This is an open label, multi-center, Phase I study to assess the safety of administering MV-NIS directly into the tumor bed (for locally recurrent medulloblastoma or ATRT patients) or into the subarachnoid space (for disseminated recurrent medulloblastoma or ATRT patients). For locally recurrent patients (patients in the first arm) MV-NIS ...

Phase

3.73 miles

Learn More »